KEQUNasdaqLaboratory Apparatus & FurnitureFiscal year ends April 30
KEWAUNEE SCIENTIFIC CORP /DE/
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026
$32.10−0.82 (-2.51%)
Close on Oct 19, 2026
- Market cap
- $93.76M
- P/E (TTM)
- 11.6
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
28.5%+12.3 pts over 5 years
Operating margin
5.9%+6.8 pts over 5 years
Net margin
3.4%+5.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.3% | +8.7% | +13.8% | +8.2% | |
| Gross profit | +16.8% | +31.2% | +27.4% | +13.0% | |
| Operating income | -5.9% | +46.1% | – | +11.4% | |
| Net income | -15.7% | +135.3% | – | +9.7% | |
| EPS, diluted | -15.9% | +134.4% | – | +8.5% | |
| Free cash flow | +16.5% | – | – | +11.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 11.1% | -9.2% | 13.8% | |
| Return on assets | 5.9% | -4.2% | 5.2% | |
| Current ratio | 2.22 | 1.77 | 2.18 | |
| Debt to equity | – | – | 0.27 | |
| Net debt to EBITDA | – | – | 0.44× | |
| Interest coverage | 22.4× | -3.4× | 4.3× | |
| Inventory turnover | 7.3× | 7.8× | 6.4× | |
| Capex to revenue | 1.9% | 1.6% | 1.4% | |
| Diluted shares | 3M | 3M | 3M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Kewaunee Scientific generated $64.66M from operations and spent $20.13M on capital expenditure, dividends and share buybacks. 82% of that went back into the business.
Generated
$64.66M
Used
$20.13M
Capital expenditure$16.53M82%Dividends$00%Share buybacks$3.59M18%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin3.4%
×Asset turnover1.51×
×Equity multiplier2.68×
=Return on equity, FY202613.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 3.4% | 1.51× | 2.68× | 13.8% |
| FY2025 | 4.7% | 1.46× | 2.76× | 19.1% |
| FY2024 | 9.2% | 1.61× | 2.75× | 40.7% |
| FY2023 | 0.3% | 1.85× | 3.25× | 2.0% |
| FY2022 | -3.6% | 1.62× | 2.71× | -15.9% |
| FY2021 | -2.5% | 1.70× | 2.18× | -9.2% |
| FY2020 | -3.2% | 1.72× | 2.00× | -11.0% |
| FY2019 | 1.0% | 1.70× | 1.82× | 3.2% |
| FY2018 | 3.3% | 1.90× | 1.82× | 11.6% |
| FY2017 | 3.3% | 1.81× | 1.88× | 11.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
4of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$9.62M
- Cash generatingOperating cash flow above zero$18.63M
- Return on assets improvedROA up on the prior year8.5% → 4.9%
- Earnings backed by cashOperating cash flow above net income$18.63M vs $9.62M
- Less leverageLong-term debt to assets fell17.8% → 8.5%
- Better liquidityCurrent ratio rose2.20 → 2.18
- No dilutionShare count did not rise3M → 3M
- Gross margin improvedGross margin up on the prior year28.63% → 28.52%
- More efficientAsset turnover rose1.78 → 1.45